ASP Isotopes (NASDAQ:ASPI) Director Sells $649,186.08 in Stock

Key Points

• ASP Isotopes Director Todd Wider sold 74,108 shares for a total of $649,186.08, reducing their ownership by 9.45%.
• The company reported a quarterly loss of ($1.03) earnings per share, significantly missing expectations of ($0.11).
• Analysts have set a price target range for ASP Isotopes, with Canaccord Genuity issuing a "buy" rating at $11.00 while the average target is $7.75.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director Todd Wider sold 74,108 shares of ASP Isotopes stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $8.76, for a total transaction of $649,186.08. Following the sale, the director owned 710,230 shares of the company's stock, valued at approximately $6,221,614.80. The trade was a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ASP Isotopes Stock Performance

Shares of ASPI traded up $0.35 during trading hours on Friday, hitting $9.34. The stock had a trading volume of 6,773,846 shares, compared to its average volume of 5,254,803. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. The firm has a 50-day moving average price of $9.53 and a 200 day moving average price of $7.73. ASP Isotopes Inc. has a fifty-two week low of $2.78 and a fifty-two week high of $11.86.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.92). The company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. As a group, research analysts forecast that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

ASPI has been the subject of several recent research reports. Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price objective on shares of ASP Isotopes in a research note on Wednesday, September 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of ASP Isotopes in a research note on Saturday, September 27th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, ASP Isotopes presently has a consensus rating of "Hold" and an average target price of $7.75.

Hedge Funds Weigh In On ASP Isotopes

A number of institutional investors have recently modified their holdings of ASPI. BNP Paribas Financial Markets acquired a new position in ASP Isotopes in the 4th quarter valued at $34,000. Ameritas Investment Partners Inc. increased its stake in ASP Isotopes by 41.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company's stock valued at $40,000 after buying an additional 1,600 shares during the period. SBI Securities Co. Ltd. increased its stake in ASP Isotopes by 84.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after buying an additional 4,299 shares during the period. Millennium Management LLC acquired a new position in ASP Isotopes in the 4th quarter valued at $55,000. Finally, Fortitude Advisory Group L.L.C. acquired a new position in ASP Isotopes in the 1st quarter valued at $64,000. 16.80% of the stock is owned by institutional investors and hedge funds.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.